Increased levels of soluble Fas in serum from diabetic patients with neuropathy

Citation
R. Guillot et al., Increased levels of soluble Fas in serum from diabetic patients with neuropathy, DIABETE MET, 27(3), 2001, pp. 315-321
Citations number
28
Categorie Soggetti
Endocrinology, Nutrition & Metabolism
Journal title
DIABETES & METABOLISM
ISSN journal
12623636 → ACNP
Volume
27
Issue
3
Year of publication
2001
Pages
315 - 321
Database
ISI
SICI code
1262-3636(200106)27:3<315:ILOSFI>2.0.ZU;2-H
Abstract
Objective: The aim of this study was to investigate circulating soluble Pas (sFas) and Fas ligand (sFasL), two transmembrane glycoproteins involved in apoptosis, in the serum of diabetic patients. Material and methods: We assessed sFas and sFasL serum levels in normal con trols (n = 15), and in both 42 diabetic patients without complications, or with predominant retinopathy or neuropathy, using sFas and sFasL specific E LISA method. Results: sFasL serum levels were less than 0.1 ng/ml in normal controls and in each group of diabetic patients. In diabetic patients with a predominan t neuropathy, sFas serum levels were significantly increased not only when compared with normal controls (13.5 +/- 3.6 ng/ml vs 7.1 +/- 1.1 ng/ml, p < 0.001), but also when compared with patients without complications ( vs 9. 1 +/- 1.8 ng/ml, p < 0.001) or with a predominant retinopathy (Vs 8.7 +/- 1 .9 ng/ml, p < 0.001). Conclusions: These preliminary data suggest that a dysregulation of the Fas system in peripheral neuronal cells may be involved in the increase of sFa s observed in diabetic patients with neuropathy.